Hammerson PLC

Director's Dealing • Nov 10, 2022

National Storage Mechanism | Additional information

RNS Number : 8801F

Hammerson PLC

10 November 2022

Hammerson plc (the "Company")

Notification of Transactions of Directors and PDMRs

10 November 2022

The Company has been notified that Méka Brunel, a Non-Executive Director of the Company, received 2,875 ordinary 5 pence shares in the Company pursuant to the Company's Enhanced Scrip Dividend Alternative at GBP 2 pence or 38.975 ZAR cents per share as announced on 28 July 2022 (the "Enhanced Scrip Dividend Alternative").

This announcement is made in accordance with the requirements of the UK Market Abuse Regulation. The notification of dealing forms can be found below.

Richard Crowle

Assistant Company Secretary

+44 (0) 20 7887 1000

Notification of dealing form

1

Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated

a)

Name

Méka Brunel

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification

/Amendment

Initial notification

3

Details of the issuer

a)

Name

Hammerson plc

b)

LEI

213800G1C9KKVVDN1A60

4

Details of the transaction(s): section to be repeated for (i) each type of instrument;

(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument.

Identification code

Ordinary 5 pence shares

ISIN: GB00BK7YQK64

b)

Nature of the transaction

Acquisition of ordinary shares of 5 pence pursuant to the Enhanced Scrip Dividend Alternative.

c)

Price(s) and volume(s)

	Price(s)	Volume(s)
	£0.1992	2,875

d)

Aggregated information

-     Aggregated volume

-     Price

	Aggregate Price	Aggregate Volume	Aggregate Total
	£0.1992	2,875	£572.70

e)

Date of the transaction

3 November 2022

f)

Place of the transaction

London Stock Exchange (XLON)

This announcement has also been released on the SENS system of the Johannesburg Stock Exchange and on Euronext Dublin.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEASFNESEAFFA